Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid

#2891

Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.

Aim(s): To evaluate SREs and their outcomes in NEN pts with BM, treated with zoledronic acid (ZA).

Materials and methods: The diagnosis of NEN BM was based on molecular and/or cross-sectional imaging. Eligible pts received at least 2 cycles of ZA and time to first SRE was defined as presence of a pathological fracture, and/or need for spinal surgery and/or external beam radiotherapy (EBR) for pain control or spinal cord compression. Time to SRE and overall survival (OS) were estimated using the Kaplan-Meier method.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Armeni E, Hayes A, Gopaul A, Aristidou I, Navalkissoor S,

Keywords: bone metastases, NEN, zoledronic acid, skeletal related event,